Ozagrel Sodium for Injection
Function and Efficacy
This product is a thromboxane synthetase inhibitor that can inhibit the production of TXA2, thus having the effects of anti-platelet aggregation and vasodilation. Animal experiments have shown that intravenous administration can reduce plasma TXB2 levels and the Keto-PGF12/TXB2 ratio, inhibit platelet aggregation caused by different inducers, and prevent cerebral infarction caused by the middle cerebral artery in rats.
Ingredients
Ozagrel sodium.
| Name | Description | Content | CAS NO. | Manufacturer |
|---|---|---|---|---|
| Ozagrel sodiumIngredients |
This product is a thromboxane synthetase inhibitor that can inhibit the production of TXA2, thus having the effects of anti-platelet aggregation and vasodilation. Animal experiments have shown that intravenous administration can reduce plasma TXB2 levels and the Keto-PGF12/TXB2 ratio, inhibit platelet aggregation caused by different inducers, and prevent cerebral infarction caused by the middle cerebral artery in rats. More |
189224-26-8 | 10 |
Appearance
This product is white or off-white loose lumps.
Indication
It is suitable for the treatment of acute thrombotic cerebral infarction and movement disorders associated with cerebral infarction.
Usage and Dosage
Adults: 40mg~80mg (2~4 vials) at a time, 1~2 times a day, dissolved in 500ml of normal saline or 5% glucose solution, continuous intravenous drip, 2 weeks as a course of treatment.
Adverse Reactions
Gastrointestinal reactions and allergic reactions, such as nausea, vomiting, urticaria, rash, etc., are relieved after appropriate treatment. A few cases may experience increased GPT and BUN, intracranial, gastrointestinal, subcutaneous bleeding, and thrombocytopenia.
Precautions
The following conditions are contraindicated: 1. Patients with hemorrhagic cerebral infarction, or deep coma due to large-area cerebral infarction; 2. Patients with severe heart, lung, liver, and kidney dysfunction, such as severe arrhythmia and myocardial infarction; 3. Patients with blood diseases or bleeding tendency; 4. Patients with severe hypertension, with systolic blood pressure exceeding 26.6kpa (i.e., more than 200 mmHg); 5. Patients who are allergic to this product.
Special Population Medication
Precautions for children: Not yet clear. Precautions for pregnancy and lactation: Use with caution in pregnant women: Others are not yet clear. Precautions for the elderly: Due to the low physiological function of the elderly, the drug should be used with caution.
Drug Interactions
Avoid mixing with calcium-containing infusions.
Storage
Keep away from light and store in a sealed container.
Packaging Specification
80mg
Validity Period
24 months
Manufacturer
Dalian Tianyu Pharmaceutical Co., Ltd.
-
Founded in:
1997-09-16 -
Address:
Houshi, Jinzhou District, Dalian City, Liaoning Province -
Tax NO.:
91210213241831622W -
Registered Funds:
7.01427 million yuan -
Website:
-
Email: